Navigation Links
OpenQ is Awarded Prestigious Life Sciences Industry Award

OpenQ wins the 2009 Global Pharmaceutical CRM Growth Strategy Leadership of the Year presented by Frost & Sullivan

Charlottesville, VA, New York, NY and Paris, France (PRWEB) June 15, 2009 -- OpenQ, one of the industry leaders in KOL management solutions and MSL performance tools, announces that it has received the prestigious 2009 Global Pharmaceutical CRM Growth Strategy Leadership of the Year award, presented by Frost & Sullivan to the company that has demonstrated an exceptional growth strategy within the industry.

A recipient is chosen to receive the Frost & Sullivan Award for CRM Growth Strategy Leadership of the Year based on specific criteria. Through primary and secondary research methods, all companies' market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company consistently shows high growth rates, it is a candidate for the Frost & Sullivan Award Growth Strategy Leadership of the Year.

This accolade is given to the company that has bolstered their position in the market during the base year and whose strategy will have a profound and lasting impact on the market. The award criteria consist of the following:

  • Ability to grow in a saturated or maturing market
  • Implementing a unique sales strategy
  • Technological innovation and leadership
  • Discovering new venues for an established product
  • Effective Internet strategy
  • Strategic mergers, acquisitions, or joint ventures to penetrate new markets
  • Reorganization structured around growth strategy

About openQ:
OpenQ provides the integrated insights and software solutions to meet the critical compliance, KOL, content and speaker needs facing Life Science companies, from development stage through maturity. Achieving another year of exponential growth, openQ serves its customers from various locations across North America, South America, Europe and Asia. OpenQ's growing list of customers includes 7 of the Top 10 pharmaceutical and 3 of the Top 5 medical device companies. For more information, visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
2. Proplant Awarded Qatar Project
3. Plexus Awarded Development Contract With QIAGEN
4. Enerkem GreenField Alberta Biofuels Awarded Permit to Build Worlds First Commercial Municipal Waste-to-Biofuels Facility
5. ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program
6. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
7. ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
8. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
9. PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
10. Transgenomic Awarded Clinical Laboratory Certification in California
11. OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimers Disease
Post Your Comments:
Related Image:
OpenQ is Awarded Prestigious Life Sciences Industry Award
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):